These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 12050550)

  • 1. Antisense oligonucleotide therapy in urology.
    Kausch I; Böhle A
    J Urol; 2002 Jul; 168(1):239-47. PubMed ID: 12050550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Basics of antisense oligonucleotide therapy and current therapeutical strategies in urology].
    Kausch I; Böhle A
    Aktuelle Urol; 2003 Dec; 34(7):458-68. PubMed ID: 14655082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
    Frankel SR
    Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense oligonucleotide technology: from EST to therapeutics.
    Giles RV
    Curr Opin Mol Ther; 2000 Jun; 2(3):238-52. PubMed ID: 11249617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAF antisense oligonucleotide as a tumor radiosensitizer.
    Kasid U; Dritschilo A
    Oncogene; 2003 Sep; 22(37):5876-84. PubMed ID: 12947394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antisense oligonucleotides are clinically tested. They inhibit the expression of disease-related genes].
    Sommer W; Heilig M
    Lakartidningen; 1999 Jan; 96(4):348-54. PubMed ID: 10024826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AEG-35156, an antisense oligonucleotide against X-linked inhibitor of apoptosis for the potential treatment of cancer.
    Tamm I
    Curr Opin Investig Drugs; 2008 Jun; 9(6):638-46. PubMed ID: 18516763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy.
    Cho YS; Cho-Chung YS
    Clin Cancer Res; 2003 Mar; 9(3):1171-8. PubMed ID: 12631623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R; Carbone R; Reiss M; Lacy J
    Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense oligonucleotide therapy in cancer.
    Stephens AC; Rivers RP
    Curr Opin Mol Ther; 2003 Apr; 5(2):118-22. PubMed ID: 12772500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense oligonucleotides as therapeutic agents.
    Galderisi U; Cascino A; Giordano A
    J Cell Physiol; 1999 Nov; 181(2):251-7. PubMed ID: 10497304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.
    Oberbauer R
    Wien Klin Wochenschr; 1997 Jan; 109(2):40-6. PubMed ID: 9123943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bcl-XL antisense oligonucleotides coupled with antennapedia enhances radiation-induced apoptosis in pancreatic cancer.
    Masui T; Hosotani R; Ito D; Kami K; Koizumi M; Mori T; Toyoda E; Nakajima S; Miyamoto Y; Fujimoto K; Doi R
    Surgery; 2006 Aug; 140(2):149-60. PubMed ID: 16904964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of antisense oligonucleotides in the treatment of bladder cancer.
    Duggan BJ; Gray S; Johnston SR; Williamson K; Miyaki H; Gleave M
    Urol Res; 2002 Jul; 30(3):137-47. PubMed ID: 12111175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense molecules for targeted cancer therapy.
    Wacheck V; Zangemeister-Wittke U
    Crit Rev Oncol Hematol; 2006 Jul; 59(1):65-73. PubMed ID: 16750913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy.
    Kim R; Emi M; Matsuura K; Tanabe K
    Cancer Gene Ther; 2007 Jan; 14(1):1-11. PubMed ID: 17041564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans.
    Iversen PL; Arora V; Acker AJ; Mason DH; Devi GR
    Clin Cancer Res; 2003 Jul; 9(7):2510-9. PubMed ID: 12855625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response of bladder carcinoma cells to TRAIL and antisense oligonucleotide, Bcl-2 or clusterin treatments.
    Sun B; Moibi JA; Mak A; Xiao Z; Roa W; Moore RB
    J Urol; 2009 Mar; 181(3):1361-71. PubMed ID: 19157446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.